Leriglitazone hydrochloride

Catalog No.: C09-1142-412
Mfr. No.: L647634-5mg
Mfr. Name: Aladdin Scientific
Qty/UOM: 1
UOM: EA

Price: $937.58

List Price: $1,041.76

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Leriglitazone (Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a K i of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC 50 of 680 nMForm:SolidIC50& Target:PPAR-γ. Specification: ≥99.0% Molecular Formula: C19H21ClN2O4S Molecular Weight: 408.9 PubChem CID: 86748889 Isomeric SMILES: CC(C1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3)O.Cl

UPC:: 51183706
Condition:: New
Availability:: 8-12 weeks
Weight:: 1.06 Ounces
HazmatClass:: No
WeightUOM:: LB
MPN:: L647634-5mg
CAS:: 146062-46-6
Product Size:: 5mg

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."